Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CELULARITY INC-A (CELU) Stock Price & Overview
NASDAQ:CELU • US1511902041
Current stock price
0.957 USD
+0.02 (+2.43%)
At close:
1.11 USD
+0.15 (+15.99%)
After Hours:
The current stock price of CELU is 0.957 USD. Today CELU is up by 2.43%. In the past month the price decreased by -28.05%. In the past year, price decreased by -40%.
CELU Key Statistics
52-Week Range0.9305 - 4.35
Current CELU stock price positioned within its 52-week range.
1-Month Range0.9305 - 1.45
Current CELU stock price positioned within its 1-month range.
- Market Cap
- 27.6M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.34
- Dividend Yield
- N/A
CELU Stock Performance
Today
+2.43%
1 Week
-13.78%
1 Month
-28.05%
3 Months
-21.56%
Longer-term
6 Months -50.92%
1 Year -40.00%
2 Years -69.23%
3 Years -87.41%
5 Years N/A
10 Years N/A
CELU Stock Chart
CELU Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CELU. When comparing the yearly performance of all stocks, CELU is a bad performer in the overall market: 90.67% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
CELU Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CELU. Both the profitability and financial health of CELU have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CELU Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateNov 17, 2025
PeriodQ3 / 2025
EPS Reported-$0.88
Revenue Reported
EPS Surprise 42.48%
Revenue Surprise %
CELU Forecast & Estimates
7 analysts have analysed CELU and the average price target is 6.12 USD. This implies a price increase of 539.5% is expected in the next year compared to the current price of 0.957.
For the next year, analysts expect an EPS growth of -752.63% and a revenue growth 27.37% for CELU
Analysts
Analysts82.86
Price Target6.12 (539.5%)
EPS Next Y-752.63%
Revenue Next Year27.37%
CELU Index Membership
CELU is currently included in the following stock indexes tracked on ChartMill.
CELU Financial Highlights
Over the last trailing twelve months CELU reported a non-GAAP Earnings per Share(EPS) of -3.34. The EPS decreased by -119.42% compared to the year before.
Income Statements
Revenue(TTM)40.58M
Net Income(TTM)-80.71M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.65% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%-19.97%
Sales Q2Q%-43.16%
EPS 1Y (TTM)-119.42%
Revenue 1Y (TTM)-15.81%
CELU Ownership
Ownership
Inst Owners12.94%
Shares28.84M
Float18.05M
Ins Owners15.43%
Short Float %1.25%
Short Ratio1.23
CELU Industry Overview
CELU operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
CELU Latest News, Press Relases and Analysis
CELU Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CELU
Company Profile
Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey and currently employs 123 full-time employees. The company went IPO on 2019-05-23. The firm is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. The company develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Company Info
IPO: 2019-05-23
CELULARITY INC-A
170 Park Ave
Florham Park NEW JERSEY US
Employees: 123
Phone: 19087682170
CELULARITY INC-A / CELU FAQ
What does CELULARITY INC-A do?
Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey and currently employs 123 full-time employees. The company went IPO on 2019-05-23. The firm is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. The company develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
What is the stock price of CELULARITY INC-A today?
The current stock price of CELU is 0.957 USD. The price increased by 2.43% in the last trading session.
What is the dividend status of CELULARITY INC-A?
CELU does not pay a dividend.
What is the ChartMill rating of CELULARITY INC-A stock?
CELU has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does CELULARITY INC-A belong to?
CELULARITY INC-A (CELU) operates in the Health Care sector and the Biotechnology industry.
Should I buy CELU stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CELU.
Can you provide the growth outlook for CELULARITY INC-A?
The Revenue of CELULARITY INC-A (CELU) is expected to grow by 27.37% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.